Navigation Links
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Date:5/13/2008

said Paul LaViolette, Chief Operating Officer of Boston Scientific. "With the anticipated FDA approval of the XIENCE V (PROMUS) Stent and the launch of the TAXUS Liberte Stent this year, we are excited to offer physicians and their patients two drugs on two highly deliverable platforms."

The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. The PROMUS and TAXUS Liberte(R) Stents have received CE Mark approval and are distributed in most European countries and other international markets. The XIENCE V (PROMUS) Stent is an investigational device in the U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008.

SPIRIT III is sponsored by Abbott. TAXUS, TAXUS Express2, Express, Liberte and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories Group of Companies.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance and competitive offering
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Exelixis Announces First Quarter 2008 Financial Results
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Verathon®, maker of BladderScan® bladder volume instruments ... volume ultrasound is now included in the ... of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... November 2009, replace the previous guidelines which ... are located on the Web at: ...
(Date:12/16/2009)... Greenway Medical Technologies, Inc. today announced that its ... management and interoperability solution, Prime Suite® 2011, ... annual 2009 Top 20 Best in KLAS ... ,, For practices having between six and 25 ... in KLAS in ambulatory EMR for the fourth ...
(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Dutch Top Institute Pharma Attracts International Interest 56710 1Dutch Top Institute Pharma Attracts International Interest 56710 2Cell Therapeutics Inc 28CTI 29 to Present at BioCenturys NewsMakers in the Biotech Industry Conference 13959 1Oxygen Biotherapeutics Inc Posts Latest Blog by CEO Chris Stern 56708 1
... DIEGO, May 21, 2007 /PRNewswire/ -- Asenapine -- ... business unit of Akzo Nobel, for bipolar I ... effective than placebo,in treating acute manic and mixed ... Phase III results, from a study,presented at the ...
... Data Presented at 2007 APA Meeting -, ... Data,from four new studies examining safety and ... being studied as a potential treatment for ... today at the,2007 American Psychiatric Association annual ...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:12/16/2009)... WASHINGTON The omega-3 essential fatty acids commonly ... avoid sensory overload, according to research published by ... omega-3s to the information-processing problems found in people ... Huntington,s disease; and other afflictions of the nervous ... journal Behavioral Neuroscience , provides more evidence ...
(Date:12/16/2009)... of Digital Pen and Paper technology and the provider of ... announced that it is ranked among the Fastest Growing Technology ... , ... (PRWEB) December 16, 2009 ... the capture, digitalization and management of handwritten data. Kayentis targets ...
(Date:12/16/2009)... at all-time low, government report shows, , , WEDNESDAY, Dec. ... United States has reached almost 78 years, a record ... in 2007, women can expect to live to 80.4 ... to the report from the U.S. Centers for Disease ... can expect to live longer than their parents, life ...
(Date:12/16/2009)... FRESNO, Calif., Dec. 16 New ... that bioactive compounds in pistachios, and molecules ... ,, Pistachio oil decreases levels of an ... with tetratricopeptide repeats 2). Inflammation is a ... damaged cells or irritants, and it underlies ...
(Date:12/16/2009)... of diagnostic procedures in cardiology. The idea of publishing ... expertise of European cardiovascular imagers, is therefore long awaited. ... written with a patient rather than technology-based approach, helping ... the aid of imaging. , The book is ... and practice of cardiac imaging and its clinical use ...
Breaking Medicine News(10 mins):Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3
... the tissue abnormalities, or lesions, that typically precede cervical ... genotypes// of the human papillomavirus (HPV) than previously reported, ... of Cancer Epidemiology, Biomarkers & Prevention. ,Although ... opening to the womb can harbor multiple HPV types, ...
... Medical Center is among 10 institutions selected to oversee ... critical trauma// and sudden cardiac arrest. ,The ... and Canadian agencies to fund the $50 million Resuscitation ... in 10 North American regions. ,The centers ...
... battle super bugs, including MRSA, has found its way to ... as Tygacil, is one of the few new antibiotics to ... ,Micro organisms have undergone mutations that enabled them ... infections, such as MRSA, in hospitals. ,The new ...
... the human brain to enhance memories like the ability to ... previous studies had established the benefits of sleep for non-declarative ... on a keyboard. It was explained that the new experiment ... the facts for a test, where in the brain's hippocampus ...
... Medical Sciences (MIMS) is planning to launch a chain of ... a group of non-resident Indian (NRI) doctors residing in Gulf ... land in Kottakal in Malappuram district of the state for ... newspaper. ,MIMS chairman Azad Moopen told the newspaper ...
... Safety Authority (NZFSA) has warned people against consuming uncooked ... clearly labelled as requiring to be cooked before consuming. ... to sometimes carry norovirus, which causes a gastrointestinal illness. ... are packed frozen in 1kg bags and labeled according ...
Other Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Medical Center to Test Methods of Improving Cardiac Arrest, Trauma Survival 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Sleep Essential For A Strong Memory 2
... an extra-high transmission rate, especially in ... to the CFI plan Achromat series, ... observation and photomicrography. Because of ... as multipurpose objectives for brightfield, fluorescence, ...
Zeiss offers a full range of filter sets for a variety of applications....
... exceptional quality for this class of objectives. ... dramatically improved with performance similar to the ... also corrected for spherical aberration and provide ... of view. The DL phase contrast objectives ...
... superb field flatness, high UV transmission ... extra long working distances, these objectives ... with inverted microscopes. Because of their ... ELWD DM,objectives can be used universally ...
Medicine Products: